FDA Grants Breakthrough Designation to Rare Pediatric and Orphan Drug for Dravet Syndrome
Longboard Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational drug, Bexicaserin.
This drug is being developed for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in patients aged two years and older.
The Breakthrough Therapy designation is designed to accelerate the development and regulatory review of drugs aimed at treating serious or life-threatening conditions.
This designation is granted when preliminary clinical evidence shows that the drug may offer a significant improvement over existing treatments for at least one clinically important measure.
With this status, Bexicaserin will receive enhanced guidance from the FDA to ensure an efficient development programme, involving senior management in the regulatory process.
Advancing its research to potentially offer new treatment options for DEE patients. Many individuals with DEEs currently have limited access to novel therapies, and this milestone could lead to broader access to clinical trials and new treatments for underserved patients and their families.
